5/27/2008

Canadian biotech companies such as Labopharm and Cardiome Pharma have expressed their frustration over the FDA's slow approval of drugs, derailing plans and revenue growth. The agency previously cited staff shortages and inadequate funding for the delays.

Related Summaries